Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) - Full Text View - ClinicalTrials.gov

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) - Full Text View - ClinicalTrials.gov

NIAID Clinical Trial Seeks Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

An NIAID-sponsored clinical research trial is evaluating the drug Rituximab in treating systemic sclerosis-associated pulmonary arterial hypertension. Systemic sclerosis (SSc) or scleroderma is an autoimmune disease in which the immune system mistakenly attacks large areas of skin and organs such as the heart, lungs, or kidneys. Pulmonary arterial hypertension is among the most serious complications of SSc. This study looks at a new approach to treating the cause of the disease.

Visit ClinicalTrials.gov (identifier NCT01086540) to see full eligibility criteria and study site locations https://www.clinicaltrials.gov/ct2/show/NCT01086540.